FDA Inspection
Osteolife Biomedical I LLCOsteolife Biomedical I LLC – FDA Inspection, Feb 4, 2022
Record Details
This FDA Inspection record concerns Osteolife Biomedical I LLC, with an inspection on February 4, 2022, issued by the Center for Biologics Evaluation and Research, covering biologics.
- Company
- Osteolife Biomedical I LLC
- Inspection Date
- February 4, 2022
- Product Type
- Biologics
View Company Profile
ID · 6bfd2c91-c8f3-4587-9338-090c61ef0329
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1161595
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
- Enforcement
- Warning Letter
Other FDA inspections of Osteolife Biomedical I LLC
3| Date | Classification | Office | Project area |
|---|---|---|---|
| February 13, 2026 | Not classified | Florida District Office | Human Cellular, Tissue, and Gene Therapies |
| February 14, 2023 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| November 28, 2018 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Osteolife Biomedical I LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.